, ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial. (s. d.)

, Consulté 15 septembre 2019, à l'adresse ACADIA Pharmaceuticals Inc. website

M. Ackenheil, H. Bräu, A. Burkhart, A. Franke, and W. Pacha, , 1976.

, Arzneimittel-Forschung, vol.26, issue.6, pp.1156-1158

D. B. Allison, J. L. Mentore, M. Heo, L. P. Chandler, J. C. Cappelleri et al., Antipsychotic-induced weight gain : A comprehensive research synthesis, The American Journal of Psychiatry, vol.156, issue.11, pp.1686-1696, 1999.


B. Almoguera, R. Riveiro-alvarez, J. Lopez-castroman, P. Dorado, C. Vaquero-lorenzo et al., Pharmacogenetics Research in Schizophrenia, 2013.

, CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment, Pharmacogenetics and Genomics, vol.23, issue.11, pp.627-630


K. Alper, K. A. Schwartz, R. L. Kolts, and A. Khan, Seizure incidence in psychopharmacological clinical trials : An analysis of Food and Drug Administration (FDA) summary basis of approval reports, Biological Psychiatry, vol.62, issue.4, pp.345-354, 2007.


J. M. Alvir, J. A. Lieberman, A. Z. Safferman, J. L. Schwimmer, and J. A. Schaaf, Clozapineinduced agranulocytosis. Incidence and risk factors in the United States, The New England Journal of Medicine, vol.329, issue.3, pp.162-167, 1993.

A. Amar, R. H. Segman, S. Shtrussberg, L. Sherman, C. Safirman et al., An association between clozapine-induced agranulocytosis in schizophrenics and HLA, 1998.

. Dqb1*0201, The International Journal of Neuropsychopharmacology, vol.1, issue.1, pp.41-44


, Consulté 15 septembre, Statistiques et publications. (s. d.), 2019.

O. A. Andreassen, T. Macewan, A. K. Gulbrandsen, R. G. Mccreadie, and V. M. Steen, Nonfunctional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients, Psychopharmacology, vol.131, issue.2, pp.174-179, 1997.


M. Armstrong, A. K. Daly, R. Blennerhassett, N. Ferrier, and J. R. Idle, Antipsychotic druginduced movement disorders in schizophrenics in relation to CYP2D6 genotype, The British Journal of Psychiatry: The Journal of Mental Science, vol.170, pp.23-26, 1997.


M. Arranz, D. Collier, M. Sodhi, D. Ball, G. Roberts et al., Association between clozapine response and allelic variation in 5-HT2A receptor gene, Lancet, issue.8970, pp.281-282, 1995.

M. J. Arranz, J. Munro, J. Birkett, A. Bolonna, D. Mancama et al., Pharmacogenetic prediction of clozapine response, Lancet, issue.9215, pp.1615-1616, 2000.

M. J. Arranz, J. Munro, M. J. Owen, G. Spurlock, P. C. Sham et al., Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine, Molecular Psychiatry, vol.3, issue.1, pp.61-66, 1998.

C. Asenjo-lobos, K. Komossa, C. Rummel-kluge, H. Hunger, F. Schmid et al., Clozapine versus other atypical antipsychotics for schizophrenia. The Cochrane Database of Systematic Reviews, 2010.

M. C. Athanasiou, M. Dettling, I. Cascorbi, I. Mosyagin, B. A. Salisbury et al., Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis, The Journal of Clinical Psychiatry, vol.72, issue.4, pp.458-463, 2011.


K. Atkin, F. Kendall, D. Gould, H. Freeman, J. Liberman et al., Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland, The British Journal of Psychiatry: The Journal of Mental Science, vol.169, issue.4, pp.483-488, 1996.


N. Aymard, C. Baldacci, A. Leyris, P. O. Smagghe, S. Tribolet et al., , 1997.

, Neuroleptic-resistant schizophrenic patients treated by clozapine : Clinical evolution, plasma and red blood cell clozapine and desmethylclozapine levels, Therapie, vol.52, issue.3, pp.227-232

H. Balibey, C. Basoglu, S. Lundgren, M. O. Babaoglu, U. Yasar et al., , 2011.

. Cyp1a2*1f, Polymorphism Decreases Clinical Response to Clozapine in Patients with

, Schizophrenia. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology, vol.21, issue.2, pp.93-99

C. Barbui, A. Signoretti, S. Mulè, M. Boso, and A. Cipriani, Does the addition of a second antipsychotic drug improve clozapine treatment?, Schizophrenia Bulletin, vol.35, issue.2, pp.458-468, 2009.


J. Barclay, B. Mccollum, G. Schoretsanitis, and J. De-leon, Gemfibrozil May Decrease Norclozapine Elimination : A Case Report, Journal of Clinical Psychopharmacology, vol.39, issue.4, pp.405-407, 2019.

L. Z. Benet and B. Hoener, Changes in plasma protein binding have little clinical relevance, Clinical Pharmacology and Therapeutics, vol.71, issue.3, pp.115-121, 2002.


L. Bertilsson, J. Carrillo, M. Dahl, A. Llerena, C. Alm et al., Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test, British Journal of Clinical Pharmacology, vol.38, issue.5, pp.471-473, 1994.

J. Bobon, D. P. Bobon, A. Pinchard, J. Collard, T. A. Ban et al., A new comparative physiognomy of neuroleptics : A collaborative clinical report, Acta Psychiatrica Belgica, vol.72, issue.5, pp.542-554, 1972.

H. Bräu, A. Burkhart, W. Pacha, and M. Ackenheil, , 1978.

, Arzneimittel-Forschung, vol.28, issue.8, p.1300

K. Broich, S. Heinrich, and A. Marneros, Acute clozapine overdose : Plasma concentration and outcome, Pharmacopsychiatry, vol.31, issue.4, pp.149-151, 1998.

P. Buckley, A. Miller, J. Olsen, D. Garver, D. D. Miller et al., When symptoms persist : Clozapine augmentation strategies, Schizophrenia Bulletin, vol.27, issue.4, pp.615-628, 2001.


J. A. Carrillo, A. G. Herraiz, S. I. Ramos, and J. Benítez, Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients, Journal of Clinical Psychopharmacology, vol.18, issue.4, pp.311-316, 1998.

W. H. Chang, S. K. Lin, H. Y. Lane, W. H. Hu, M. W. Jann et al., Clozapine dosages and plasma drug concentrations, Journal of the Formosan Medical Association = Taiwan Yi Zhi, vol.96, issue.8, pp.599-605, 1997.

W. Chang, B. Augustin, H. Lane, T. Zumbrunnen, H. Liu et al., , 1999.

, In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine, Psychopharmacology, vol.145, issue.1, pp.91-98

P. Chen, J. Lin, C. Lu, C. Ong, P. F. Hsieh et al., Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan, New England Journal of Medicine, vol.364, issue.12, pp.1126-1133, 2011.

S. A. Chong, C. H. Tan, Y. M. Khoo, H. S. Lee, K. E. Wong et al., Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia, 1997.

, Therapeutic Drug Monitoring, vol.19, issue.2, pp.219-223

N. Chopra and J. De-leon, Clozapine-induced myocarditis may be associated with rapid titration : A case report verified with autopsy, International Journal of Psychiatry in Medicine, vol.51, issue.1, pp.104-115, 2016.

A. Cipriani, M. Boso, and C. Barbui, Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia, The Cochrane Database of Systematic Reviews, issue.3, 2009.

D. Cohen, Clozapine and Gastrointestinal Hypomotility, CNS Drugs, issue.12, pp.1083-1091, 2017.

R. R. Conley, W. T. Carpenter, and C. A. Tamminga, Time to clozapine response in a standardized trial, The American Journal of Psychiatry, vol.154, issue.9, pp.1243-1247, 1997.


S. Crettol, J. Déglon, J. Besson, M. Croquette-krokar, R. Hämmig et al., ABCB1 and cytochrome P450 genotypes and phenotypes : Influence on methadone plasma levels and response to treatment, Clinical Pharmacology and Therapeutics, vol.80, issue.6, pp.668-681, 2006.


A. David, A. Fernandez, M. Menard, E. Dor, G. Leali et al., , 2019.

, Pharmacorésistance aux psychotropes et anomalies pharmacogénétiques du cytochrome P450 2D6 : Vers une médecine personnalisée en pédopsychiatrie, présentation d'un protocole de recherche, vol.67, pp.109-117


M. A. Davies, B. A. Compton-toth, S. J. Hufeisen, H. Y. Meltzer, and B. L. Roth, The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a 132 common property of either typical or atypical antipsychotic drugs : Is M1 agonism a prerequisite for mimicking clozapine's actions?, Psychopharmacology, vol.178, issue.4, pp.451-460, 2005.


R. B. De-brito, L. De-carvalho-araújo, M. J. Diniz, R. De-castro-georg, J. C. Nabout et al., The CYP1A2 -163C > A polymorphism is associated with superrefractory schizophrenia, Schizophrenia Research, vol.169, issue.1-3, pp.502-503, 2015.


J. De-leon, Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics, 2019.

J. De-leon, A. Odom-white, R. C. Josiassen, F. J. Diaz, T. B. Cooper et al., Serum antimuscarinic activity during clozapine treatment, Journal of Clinical Psychopharmacology, vol.23, issue.4, pp.336-341, 2003.

J. De-leon, V. Santoro, C. D'arrigo, and E. Spina, Interactions between antiepileptics and second-generation antipsychotics, Expert Opinion on Drug Metabolism & Toxicology, vol.8, issue.3, pp.311-334, 2012.

J. Delay, P. Deniker, and J. M. Harl, , 1952.

, Annales Medico-Psychologiques, vol.110, issue.2, pp.112-117

A. Demjaha, R. M. Murray, P. K. Mcguire, S. Kapur, and O. D. Howes, Dopamine synthesis capacity in patients with treatment-resistant schizophrenia, The American Journal of Psychiatry, vol.169, issue.11, pp.1203-1210, 2012.

M. Dettling, I. Cascorbi, I. Roots, and B. Mueller-oerlinghausen, Genetic determinants of clozapine-induced agranulocytosis : Recent results of HLA subtyping in a non-jewish caucasian sample, Archives of General Psychiatry, vol.58, issue.1, pp.93-94, 2001.


O. Devinsky, G. Honigfeld, and J. Patin, Clozapine-related seizures, Neurology, vol.41, issue.3, pp.369-371, 1991.

X. Ding and L. S. Kaminsky, Human extrahepatic cytochromes P450 : Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts, Annual Review of Pharmacology and Toxicology, vol.43, pp.149-173, 2003.


L. B. Dixon, F. Dickerson, A. S. Bellack, M. Bennett, D. Dickinson et al., ? Schizophrenia Patient Outcomes Research Team (PORT). (2010). The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements, Schizophrenia Bulletin, vol.36, issue.1, pp.48-70


Z. Djerada, F. Daviet, P. Llorca, A. Eschalier, F. Saint-marcoux et al., Suivi thérapeutique pharmacologique de la clozapine, 2016.

M. Dobrinas, J. Cornuz, B. Oneda, M. Kohler-serra, M. Puhl et al., Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility, Clinical Pharmacology and Therapeutics, vol.90, issue.1, pp.117-125, 2011.

B. I. Drögemöller, R. Emsley, B. Chiliza, L. Van-der-merwe, G. E. Wright et al., The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patients, Pharmacogenetics and Genomics, vol.26, issue.5, pp.235-242, 2016.

C. B. Eap, S. Bender, E. Sirot, G. Cucchia, M. Jonzier-perey et al., Nonresponse to clozapine and ultrarapid CYP1A2 activity : Clinical data and analysis of CYP1A2 gene, Journal of Clinical Psychopharmacology, vol.24, issue.2, pp.214-219, 2004.


C. B. Eap, S. Bender, E. J. Sirot, G. Cucchia, M. Jonzier-perey et al., , 2004.

. Nonresponse-to-clozapine, . Ultrarapid, and . Activity, Clinical Data and Analysis of CYP1A2 Gene, Journal of Clinical Psychopharmacology, vol.24, issue.2, pp.214-219


M. Eichelbaum, M. Ingelman-sundberg, and W. E. Evans, Pharmacogenomics and individualized drug therapy, Annual Review of Medicine, vol.57, pp.119-137, 2006.


D. J. Freeman and L. K. Oyewumi, Will routine therapeutic drug monitoring have a place in clozapine therapy, Clinical Pharmacokinetics, vol.32, issue.2, pp.93-100, 1997.


I. Gaertner, H. J. Gaertner, R. Vonthein, and K. Dietz, Therapeutic drug monitoring of clozapine in relapse prevention : A five-year prospective study, Journal of Clinical Psychopharmacology, vol.21, issue.3, pp.305-310, 2001.

D. Garfinkel, Studies on pig liver microsomes. I. Enzymic and pigment composition of different microsomal fractions, Archives of Biochemistry and Biophysics, vol.77, issue.2, pp.493-509, 1958.


B. N. Gaynes, A. J. Rush, M. H. Trivedi, S. R. Wisniewski, D. Spencer et al., The STAR*D study : Treating depression in the real world, Cleveland Clinic Journal of Medicine, vol.75, issue.1, pp.57-66, 2008.

G. Gentile, M. Borro, N. Lala, S. Missori, M. Simmaco et al., Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine, The Journal of Headache and Pain, vol.11, issue.5, pp.431-435, 2010.

F. R. Girardin, A. Poncet, A. Perrier, N. Vernaz, M. Pletscher et al., Costeffectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine, The Pharmacogenomics Journal, vol.19, issue.2, pp.211-218, 2019.


A. H. Glassman and J. T. Bigger, Antipsychotic drugs : Prolonged QTc interval, torsade de pointes, and sudden death, The American Journal of Psychiatry, vol.158, issue.11, pp.1774-1782, 2001.


J. I. Goldstein, L. F. Jarskog, C. Hilliard, A. Alfirevic, L. Duncan et al., , 2014.

, Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles, Nature Communications, vol.5, p.4757

D. Y. Gomez, V. J. Wacher, S. J. Tomlanovich, M. F. Hebert, and L. Z. Benet, The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine, Clinical Pharmacology and Therapeutics, vol.58, issue.1, pp.15-19, 1995.

A. J. Goudie, What is the clinical significance of the discontinuation syndrome seen with clozapine, Journal of Psychopharmacology, vol.14, issue.2, pp.188-190, 2000.


C. Greenwood-smith, D. I. Lubman, and D. J. Castle, Serum clozapine levels : A review of their clinical utility, Journal of Psychopharmacology, vol.17, issue.2, pp.234-238, 2003.


F. Gressier, C. Verstuyft, P. Hardy, L. Becquemont, and E. Corruble, Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors, Journal of Neural Transmission, vol.122, issue.1, pp.35-42, 1996.

F. Gressier, S. Porcelli, R. Calati, and A. Serretti, Pharmacogenetics of clozapine response and induced weight gain : A comprehensive review and meta-analysis, European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, vol.26, issue.2, pp.163-185, 2016.


Y. Guéguen, K. Mouzat, L. Ferrari, E. Tissandie, J. M. Lobaccaro et al., Cytochromes P450 : Xenobiotic metabolism, 2006.

, Annales De Biologie Clinique, vol.64, issue.6, pp.535-548

M. Häggström, . Häggström, and .  m, Medical gallery of Mikael Häggström, WikiJournal of Medicine, vol.1, issue.2, 2014.

A. Hasan, P. Falkai, T. Wobrock, J. Lieberman, B. Glenthoj et al., World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1 : Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance, The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry, vol.13, issue.5, pp.318-378, 2012.

B. J. Havaki-kontaxaki, P. P. Ferentinos, V. P. Kontaxakis, K. G. Paplos, and C. R. Soldatos, , 2006.

, Concurrent administration of clozapine and electroconvulsive therapy in clozapine-resistant schizophrenia, Clinical Neuropharmacology, vol.29, issue.1, pp.52-56

J. K. Hicks, K. Sangkuhl, J. J. Swen, V. L. Ellingrod, D. J. Müller et al., Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants : 2016 update, Clinical Pharmacology and Therapeutics, vol.102, issue.1, pp.37-44, 2017.

J. K. Hicks, J. J. Swen, C. F. Thorn, K. Sangkuhl, E. D. Kharasch et al., Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants, Clinical Pharmacogenetics Implementation Consortium, vol.93, issue.5, pp.402-408, 2013.


C. Hiemke, P. Baumann, N. Bergemann, A. Conca, O. Dietmaier et al., , 2011.

, AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry : Update, 2011.

, Pharmacopsychiatry, vol.44, issue.06, pp.195-235

C. Hiemke, N. Bergemann, H. Clement, A. Conca, J. Deckert et al., P, 2018.

, Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology : Update, pp.9-62, 2017.

D. Hinze-selch, M. Deuschle, B. Weber, I. Heuser, and T. Pollmächer, Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight, Psychopharmacology, vol.149, issue.2, pp.163-169, 2000.


O. D. Howes, F. Vergunst, S. Gee, P. Mcguire, S. Kapur et al., Adherence to treatment guidelines in clinical practice : Study of antipsychotic treatment prior to clozapine initiation, The British Journal of Psychiatry: The Journal of Mental Science, vol.201, issue.6, pp.481-485, 2012.

O. Howes, R. Mccutcheon, and J. Stone, Glutamate and dopamine in schizophrenia : An update for the 21st century, Journal of Psychopharmacology, vol.29, issue.2, pp.97-115, 2015.

R. Hwang, C. Zai, A. Tiwari, D. J. Müller, M. J. Arranz et al., Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response : Exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant, The Pharmacogenomics Journal, vol.10, issue.3, pp.200-218, 2010.

T. Kamataki, K. Nunoya, Y. Sakai, H. Kushida, and K. Fujita, Genetic polymorphism of CYP2A6 in relation to cancer, Mutation Research, vol.428, issue.1-2, p.40, 1999.

J. Kane, G. Honigfeld, J. Singer, and H. Meltzer, Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine, Archives of General Psychiatry, vol.45, issue.9, pp.789-796, 1988.

T. Kapitany, K. Meszaros, E. Lenzinger, S. D. Schindler, C. Barnas et al., Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia, Schizophrenia Research, vol.32, issue.2, pp.101-106, 1998.

J. Kirchheiner, K. Nickchen, M. Bauer, M. Wong, J. Licinio et al., Pharmacogenetics of antidepressants and antipsychotics : The contribution of allelic variations to the phenotype of drug response, Molecular Psychiatry, vol.9, issue.5, pp.442-473, 2004.


G. Kirov, A. J. Pocklington, P. Holmans, D. Ivanov, M. Ikeda et al., De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia, Molecular Psychiatry, vol.17, issue.2, pp.142-153, 2012.


M. Kluge, A. Schuld, H. Himmerich, M. Dalal, A. Schacht et al., Clozapine and olanzapine are associated with food craving and binge eating : Results from a randomized double-blind study, Journal of Clinical Psychopharmacology, vol.27, issue.6, pp.662-666, 2007.

J. E. Kootstra-ros and W. Smallegoor, d.). The cytochrome P450 CYP1A2 genetic polymorphisms Ã1F and Ã1D do not affect clozapine clearance in a group of schizophrenic patients, Ann Clin Biochem, vol.4

H. J. Koponen, E. Leinonen, and U. Lepola, Fluvoxamine increases the clozapine serum levels significantly, European Neuropsychopharmacology, vol.6, issue.1, pp.69-71, 1996.

, , pp.69-71

A. Krivoy, F. Gaughran, A. Weizman, G. Breen, and J. H. Maccabe, Gene polymorphisms potentially related to the pharmacokinetics of clozapine : A systematic review, International Clinical Psychopharmacology, vol.31, issue.4, pp.179-184, 2016.


L. Lahdelma, A. Ahokas, L. C. Andersson, J. Suvisaari, I. Hovatta et al., Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia, Journal of Clinical Psychopharmacology, vol.21, issue.1, pp.4-7, 2001.

B. Laika, S. Leucht, S. Heres, H. Schneider, and W. Steimer, Pharmacogenetics and olanzapine treatment : CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome, The Pharmacogenomics Journal, vol.10, issue.1, pp.20-29, 2010.

J. Lally, J. Tully, D. Robertson, B. Stubbs, F. Gaughran et al., Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia : A systematic review and meta-analysis, Schizophrenia Research, vol.171, issue.1-3, pp.215-224, 2016.


J. Lameh, E. Burstein, E. Taylor, D. Weiner, K. Vanover et al., Pharmacology of N-desmethylclozapine?, Pharmacology & Therapeutics, vol.115, issue.2, pp.223-231, 2007.


S. Lee, S. Ryu, S. Kim, M. Kim, S. Kim et al., Association study of 27 annotated genes for clozapine pharmacogenetics : Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response, Journal of Clinical Psychopharmacology, vol.32, issue.4, pp.441-448, 2012.

J. A. Lieberman, A. Z. Safferman, S. Pollack, S. Szymanski, C. Johns et al., Clinical effects of clozapine in chronic schizophrenia : Response to treatment and predictors of outcome, The American Journal of Psychiatry, vol.151, issue.12, pp.1744-1752, 1994.


J. A. Lieberman, B. Sheitman, M. Chakos, D. Robinson, N. Schooler et al., The development of treatment resistance in patients with schizophrenia : A clinical and pathophysiologic perspective, Journal of Clinical Psychopharmacology, vol.18, issue.2, pp.20-24, 1998.


J. A. Lieberman, J. Yunis, E. Egea, R. T. Canoso, J. M. Kane et al., HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia, Archives of General Psychiatry, vol.47, issue.10, pp.945-948, 1990.


S. Lin, S. Su, and C. Pan, Higher Plasma Drug Concentration in Clozapine-treated Schizophrenic Patients With Side Effects of Obsessive/Compulsive Symptoms: Therapeutic Drug Monitoring, vol.28, pp.303-307, 2006.

H. C. Liu, W. H. Chang, F. C. Wei, S. K. Lin, S. K. Lin et al., Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients, Therapeutic Drug Monitoring, vol.18, issue.2, pp.200-207, 1996.

A. Llerena, C. Alm, M. L. Dahl, B. Ekqvist, and L. Bertilsson, Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype, Therapeutic Drug Monitoring, vol.14, issue.2, pp.92-97, 1992.

M. L. Lu, H. Y. Lane, K. P. Chen, M. W. Jann, M. H. Su et al., Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients, The Journal of Clinical Psychiatry, issue.8, pp.594-599, 2000.

M. Lu, H. Lane, K. Chen, M. W. Jann, M. Su et al., Fluvoxamine Reduces the Clozapine Dosage Needed in Refractory Schizophrenic Patients, The Journal of Clinical Psychiatry, issue.8, pp.594-599, 2000.

M. Lu, H. Lane, S. Lin, K. Chen, and W. Chang, Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances, The Journal of Clinical Psychiatry, vol.65, issue.6, pp.766-771, 2004.

A. Mahgoub, J. R. Idle, L. G. Dring, R. Lancaster, and R. L. Smith, Polymorphic hydroxylation of Debrisoquine in man, Lancet, vol.2, issue.8038, pp.584-586, 1977.

, , pp.91430-91431

W. H. Man, J. C. Colen-de-koning, P. F. Schulte, W. Cahn, I. M. Van-haelst et al., The Effect of Glycopyrrolate on Nocturnal Sialorrhea in Patients Using Clozapine : A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial, Journal of Clinical Psychopharmacology, vol.37, issue.2, pp.155-161, 2017.


J. S. Markowitz, C. S. Brown, and T. R. Moore, Atypical antipsychotics. Part I : Pharmacology, pharmacokinetics, and efficacy, The Annals of Pharmacotherapy, vol.33, issue.1, pp.73-85, 1999.


J. L. Mcclay, D. E. Adkins, K. Aberg, S. Stroup, D. O. Perkins et al., Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics, Molecular Psychiatry, vol.16, issue.1, pp.76-85, 2011.

M. Mccormack, A. Alfirevic, S. Bourgeois, J. J. Farrell, D. Kasperavi?i?t? et al., HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans, The New England Journal of Medicine, vol.364, issue.12, pp.1134-1143, 2011.


J. Mcgraw and D. Waller, Cytochrome P450 variations in different ethnic populations, Expert Opinion on Drug Metabolism & Toxicology, vol.8, issue.3, pp.371-382, 2012.


K. I. Melkersson, M. G. Scordo, A. Gunes, and M. Dahl, Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients, The Journal of Clinical Psychiatry, vol.68, issue.5, pp.697-704, 2007.


H. Y. Meltzer, Treatment-resistant schizophrenia-The role of clozapine, Current Medical Research and Opinion, vol.14, issue.1, pp.1-20, 1997.

J. M. Meyer, Individual Changes in Clozapine Levels After Smoking Cessation : Results and a Predictive Model, Journal of Clinical Psychopharmacology, vol.21, issue.6, pp.569-574, 2001.


J. M. Meyer and S. M. Stahl, The Clozapine Handbook by, 1970.

J. Micallef, E. Fakra, and O. Blin, , 2006.

. L'encephale, , vol.32, pp.263-269

D. D. Miller, Review and management of clozapine side effects, The Journal of Clinical Psychiatry, issue.8, pp.14-17, 2000.

P. R. Montellano and . De-(éd, Cytochrome P450 : Structure, Mechanism, and Biochemistry, 2005.

A. Montpetit, M. Nelis, P. Laflamme, R. Magi, X. Ke et al., An evaluation of the performance of tag SNPs derived from HapMap in a Caucasian population, 2006.

, PLoS Genetics, vol.2, issue.3

N. Mossaheb and R. M. Kaufmann, Role of aripiprazole in treatment-resistant schizophrenia, Neuropsychiatric Disease and Treatment, vol.8, pp.235-244, 2012.

F. Mouaffak, O. Kebir, V. Picard, L. Bonhomme-faivre, B. Millet et al., , 2011.

, Ultra-resistant schizophrenia is not associated with the multidrug-resistant transporter 1 (MDR1) gene rs1045642 variant, Journal of Clinical Psychopharmacology, vol.31, issue.2, pp.236-238


N. Myles, H. Myles, S. Xia, M. Large, S. Kisely et al., Meta-analysis examining the epidemiology of clozapine-associated neutropenia, Acta Psychiatrica Scandinavica, vol.138, issue.2, pp.101-109, 2018.

D. W. Nebert, D. R. Nelson, M. Adesnik, M. J. Coon, R. W. Estabrook et al., The P450 superfamily : Updated listing of all genes and recommended nomenclature for the chromosomal loci, DNA, vol.8, issue.1, pp.1-13, 1989.

D. R. Nelson, Cytochrome P450 and the individuality of species, Archives of Biochemistry and Biophysics, vol.369, issue.1, pp.1-10, 1999.

D. R. Nelson, L. Koymans, T. Kamataki, J. J. Stegeman, R. Feyereisen et al., P450 superfamily : Update on new sequences, gene mapping, accession numbers and nomenclature, Pharmacogenetics, vol.6, issue.1, pp.1-42, 1996.

J. Nielsen, R. Røge, O. Schjerning, H. J. Sørensen, and D. Taylor, Geographical and temporal variations in clozapine prescription for schizophrenia, European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, vol.22, issue.11, pp.818-824, 2012.


C. Nordin, B. Almé, and U. Bondesson, CSF and serum concentrations of clozapine and its demethyl metabolite : A pilot study, Psychopharmacology, vol.122, issue.2, pp.104-107, 1995.


L. A. Nussbaum, V. Dumitra?cu, A. Tudor, R. Gr?dinaru, N. Andreescu et al., , 2014.

, Molecular study of weight gain related to atypical antipsychotics : Clinical implications of the CYP2D6 genotype, Romanian Journal of Morphology and Embryology = Revue Roumaine De Morphologie Et Embryologie, vol.55, issue.3, pp.877-884

T. Ohno-shosaku, Y. Sugawara, C. Muranishi, K. Nagasawa, K. Kubono et al., Effects of clozapine and N-desmethylclozapine on synaptic transmission at hippocampal inhibitory and excitatory synapses, Brain Research, vol.1421, pp.66-77, 2011.


O. V. Olesen and K. Linnet, Contributions of five human cytochrome P450 isoforms to the Ndemethylation of clozapine in vitro at low and high concentrations, Journal of Clinical Pharmacology, vol.41, issue.8, pp.823-832, 2001.

T. Omura and R. Sato, A new cytochrome in liver microsomes, The Journal of Biological Chemistry, vol.237, pp.1375-1376, 1962.

N. Perroud, R. Uher, M. Y. Ng, M. Guipponi, J. Hauser et al., , 2012.

, Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project, The Pharmacogenomics Journal, vol.12, issue.1, pp.68-77


P. J. Perry, D. D. Miller, S. V. Arndt, and R. J. Cadoret, Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients, The American Journal of Psychiatry, vol.148, issue.2, pp.231-235, 1991.

D. Pessayre, , 1995.

, Gastroenterologie Clinique Et Biologique, vol.19, issue.5, pp.47-56

G. Petrides, C. Malur, R. J. Braga, S. H. Bailine, N. R. Schooler et al., Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia : A prospective, randomized study, The American Journal of Psychiatry, vol.172, issue.1, pp.52-58, 2015.


. Pharmvar, Consulté 10 octobre 2019

P. D. Pharoah, J. Abraham, and C. Caldas, Re : CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifentreated breast cancer patients, Journal of the National Cancer Institute, vol.104, issue.16, pp.1263-1264, 2012.

, , pp.1266-1268

I. Piatkov, D. Caetano, Y. Assur, S. L. Lau, M. Coelho et al., CYP2C19*17 protects against metabolic complications of clozapine treatment, The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry, vol.18, issue.7, pp.521-527, 2017.

N. Picard, J. Boyer, M. Etienne-grimaldi, . Barin-le, C. Guellec et al., Traitements personnalisés grâce à la pharmacogénétique : Niveaux de preuve et de recommandations du Réseau national de pharmacogénétique (RNPGx), Therapies, vol.72, issue.2, pp.175-183, 2017.

N. Picard, J. Boyer, M. Etienne-grimaldi, . Barin-le, C. Guellec et al., Pharmacogenetics-based personalized therapy : Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx), National Network of Pharmacogenetics (RNPGx, vol.72, issue.2, pp.185-192, 2017.


C. Polcwiartek and J. Nielsen, The clinical potentials of adjunctive fluvoxamine to clozapine treatment : A systematic review, Psychopharmacology, vol.233, issue.5, pp.741-750, 2016.


B. G. Pollock, R. E. Ferrell, B. H. Mulsant, S. Mazumdar, M. Miller et al., Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression, Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, vol.23, issue.5, pp.587-590, 2000.

, , pp.132-141

S. Porcelli, B. Balzarro, and A. Serretti, Clozapine resistance : Augmentation strategies, European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, vol.22, issue.3, pp.165-182, 2012.


S. K. Praharaj, M. Arora, and S. Gandotra, Clozapine-induced sialorrhea : Pathophysiology and management strategies, Psychopharmacology, vol.185, issue.3, pp.265-273, 2006.


R. M. Procyshyn, F. Vila-rodriguez, W. G. Honer, and A. M. Barr, Clozapine administered once versus twice daily : Does it make a difference?, Medical Hypotheses, vol.82, issue.2, pp.225-228, 2014.


S. Quaranta, J. Dupouey, R. Colle, and C. Verstuyft, Pharmacogénétique des médicaments antidépresseurs : État des connaissances et des pratiques -recommandations du Réseau national de pharmacogénétique (RNPGx), Therapies, vol.72, issue.2, pp.301-309, 2017.


A. P. Rajkumar, B. Poonkuzhali, A. Kuruvilla, M. Jacob, and K. S. Jacob, Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia, International Clinical Psychopharmacology, vol.28, issue.1, pp.50-56, 2013.

A. P. Rajkumar, B. Poonkuzhali, A. Kuruvilla, A. Srivastava, M. Jacob et al., Association between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia, Acta Neuropsychiatrica, vol.25, issue.1, pp.2-11, 2013.

S. Ramos-perdigués, R. Sauras-quecuti, A. Mané, L. Mann, C. Mundell et al., An observational study of clozapine induced sedation and its pharmacological management, European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, vol.26, issue.1, pp.156-161, 2016.


M. M. Regan, B. Leyland-jones, M. Bouzyk, O. Pagani, W. Tang et al., CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer : The breast international group 1-98 trial, Journal of the National Cancer Institute, vol.104, issue.6, pp.441-451, 2012.


, Règles de bonnes pratiques en génétique constitutionnelle à des fins médicales (hors diagnostic prénatal). (s. d.), Consulté 10 octobre 2019, à l'adresse Haute Autorité de Santé website

S. Rendic, Summary of information on human CYP enzymes : Human P450 metabolism data, Drug Metabolism Reviews, vol.34, issue.1-2, pp.83-448, 2002.

C. Research and D. E. , Table of Pharmacogenomic Biomarkers in Drug Labeling, 2019.

G. P. Reynolds, M. J. Hill, and S. L. Kirk, The 5-HT2C receptor and antipsychoticinduced weight gain-Mechanisms and genetics, Journal of Psychopharmacology, vol.20, issue.4, 2006.

, , pp.15-18

E. Richelson, Receptor pharmacology of neuroleptics : Relation to clinical effects, The Journal of Clinical Psychiatry, vol.60, issue.10, pp.5-14, 1999.

C. Ruan and J. De-leon, Thirty Years of Both Ignorance and Clinical Experience Suggest That Clozapine Intoxication During Co-Occurring Infections and Inflammation May Have Higher Morbidity and Mortality Than Is Currently Believed, Psychosomatics, vol.60, issue.2, pp.221-222, 2019.


C. Ruan, Y. Zang, C. Wang, Y. Cheng, C. Sun et al., Clozapine Metabolism in East Asians and Caucasians : A Pilot Exploration of the Prevalence of Poor Metabolizers and a Systematic Review, Journal of Clinical Psychopharmacology, vol.39, issue.2, pp.135-144, 2019.

C. Ruan, X. Zhang, W. Guo, W. Li, H. Zhuang et al., Two cases of high serum clozapine concentrations occurring during inflammation in Chinese patients, International Journal of Psychiatry in Medicine, vol.53, issue.4, pp.292-305, 2018.


M. Sabaawi, N. N. Singh, and J. De-leon, Guidelines for the use of clozapine in individuals with developmental disabilities, vol.27, pp.309-336, 2006.


C. Sachse, J. Brockmöller, S. Bauer, and I. Roots, Functional significance of a C?A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine : Short report, British Journal of Clinical Pharmacology, vol.47, issue.4, pp.445-449, 1999.


J. Scharfetter, H. R. Chaudhry, K. Hornik, K. Fuchs, W. Sieghart et al., Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients, European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, vol.10, issue.1, pp.17-20, 1999.

, Biological insights from 108 schizophrenia-associated genetic loci, Schizophrenia Working Group of the Psychiatric Genomics Consortium, vol.511, issue.7510, pp.421-427, 2014.


G. Schoretsanitis, J. M. Kane, C. Ruan, E. Spina, C. Hiemke et al., A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients, Expert Review of Clinical Pharmacology, vol.12, issue.7, pp.603-621, 2019.

P. Schulte, What is an adequate trial with clozapine? : Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia, Clinical Pharmacokinetics, vol.42, issue.7, pp.607-618, 2003.


J. Schumacher, T. G. Schulze, T. F. Wienker, M. Rietschel, and M. M. Nöthen, Pharmacogenetics of the clozapine response, Lancet, issue.9228, pp.506-507, 2000.

, , pp.74176-74179

S. Shaikh, D. A. Collier, P. C. Sham, D. Ball, K. Aitchison et al., Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia, Human Genetics, issue.6, pp.714-719, 1996.

H. Silver, M. Kushnir, and A. Kaplan, Fluvoxamine augmentation in clozapine-resistant schizophrenia : An open pilot study, Biological Psychiatry, vol.40, issue.7, pp.671-674, 1996.

, , pp.170-179

S. P. Singh, V. Singh, N. Kar, and K. Chan, Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia : Meta-analysis, The British Journal of Psychiatry: The Journal of Mental Science, vol.197, issue.3, pp.174-179, 2010.

D. Siskind, V. Siskind, and S. Kisely, Clozapine Response Rates among People with Treatment-Resistant Schizophrenia : Data from a Systematic Review and Meta-Analysis, Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, vol.62, issue.11, pp.772-777, 2017.


E. Spina, A. Avenoso, G. Facciolà, M. G. Scordo, M. Ancione et al., Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics, 2000.

, Psychopharmacology, vol.148, issue.1, pp.83-89

E. Spina and J. De-leon, Clinical applications of CYP genotyping in psychiatry, Journal of Neural Transmission, vol.122, issue.1, pp.5-28, 1996.

E. Spina, C. Hiemke, and J. De-leon, Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics, Expert Opinion on Drug Metabolism & Toxicology, vol.12, issue.4, pp.407-422, 2016.


V. Sriretnakumar, E. Huang, and D. J. Müller, Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia : An update, Expert Opinion on Drug Metabolism & Toxicology, vol.11, issue.11, pp.1709-1731, 2015.

T. S. Stroup, T. Gerhard, S. Crystal, C. Huang, and M. Olfson, Geographic and clinical variation in clozapine use in the United States, Psychiatric Services, vol.65, issue.2, pp.186-192, 2014.

S. Subramanian, B. A. Völlm, and N. Huband, Clozapine dose for schizophrenia. The Cochrane Database of Systematic Reviews, vol.6, 2017.

T. Suzuki, G. Remington, B. H. Mulsant, T. K. Rajji, H. Uchida et al., Treatment resistant schizophrenia and response to antipsychotics : A review, 2011.

, Schizophrenia Research, vol.133, issue.1-3, pp.54-62

T. Suzuki, G. Remington, B. H. Mulsant, H. Uchida, T. K. Rajji et al., Defining treatment-resistant schizophrenia and response to antipsychotics : A review and recommendation, Psychiatry Research, vol.197, issue.1-2, pp.1-6, 2012.


A. Szegedi, I. Anghelescu, J. Wiesner, S. Schlegel, H. Weigmann et al., Addition of Low-Dose Fluvoxamine to Low-Dose Clozapine Monotherapy in Schizophrenia : Drug Monitoring and Tolerability Data from a Prospective Clinical Trial, Pharmacopsychiatry, vol.32, issue.04, pp.148-153, 1999.

F. M. Theisen, S. Cichon, A. Linden, M. Martin, H. Remschmidt et al., Clozapine and weight gain, The American Journal of Psychiatry, vol.158, issue.5, 2001.

M. Thorup and R. Fog, Clozapine treatment of schizophrenic patients. Plasma concentration and coagulation factors, Acta Psychiatrica Scandinavica, vol.55, issue.2, pp.123-126, 1977.


J. Tiihonen, T. Hallikainen, O. Ryynänen, E. Repo-tiihonen, I. Kotilainen et al., Lamotrigine in treatment-resistant schizophrenia : A randomized placebo-controlled crossover trial, Biological Psychiatry, vol.54, issue.11, pp.1241-1248, 2003.

, , pp.524-533

R. Torta and F. Monaco, Atypical antipsychotics and serotoninergic antidepressants in patients with epilepsy : Pharmacodynamic considerations, Epilepsia, vol.43, issue.2, pp.8-13, 2002.


K. Tóth, G. Csukly, D. Sirok, A. Belic, Á. Kiss et al., Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics, The International Journal of Neuropsychopharmacology, vol.20, issue.7, pp.529-537, 2017.

H. Tsunoda, T. Kudo, Y. Masaki, A. Ohkubo, K. Seio et al., Biochemical behavior of N-oxidized cytosine and adenine bases in DNA polymerase-mediated primer extension reactions, Nucleic Acids Research, vol.39, issue.7, pp.2995-3004, 2011.

D. R. Uges, K. Boom, G. D. Wientjes, and J. Versteege, Therapeutic drug monitoring of clozapine : An unexpected outcome, Therapeutic Drug Monitoring, vol.22, issue.3, pp.323-324, 2000.

, Consulté 14 septembre, Variabilités pharmacocinétiques. (s. d.), 2019.

E. Vieta and F. Colom, Therapeutic options in treatment-resistant depression, Annals of Medicine, vol.43, issue.7, pp.512-530, 2011.

D. Vojvoda, K. Grimmell, M. Sernyak, and C. M. Mazure, Monozygotic twins concordant for response to clozapine, Lancet, issue.8993, p.61, 1996.

C. Wang, Z. Zhang, W. Li, Y. Zhai, Z. Cai et al., The Differential Effects of Steady-State Fluvoxamine on the Pharmacokinetics of Olanzapine and Clozapine in Healthy Volunteers, The Journal of Clinical Pharmacology, vol.44, issue.7, pp.785-792, 2004.


C. Wang, Z. Zhang, W. Li, Y. Zhai, Z. Cai et al., The Differential Effects of Steady-State Fluvoxamine on the Pharmacokinetics of Olanzapine and Clozapine in Healthy Volunteers, The Journal of Clinical Pharmacology, vol.44, issue.7, pp.785-792, 2004.


R. Weinshilboum, Inheritance and drug response, The New England Journal of Medicine, vol.348, issue.6, pp.529-537, 2003.

N. Yamaki, A. Hishimoto, I. Otsuka, T. Sasada, S. Boku et al., Optimizing outcomes in clozapine rechallenge following neutropenia using human leukocyte antigen typing : A case report, Psychiatry and Clinical Neurosciences, vol.71, issue.4, pp.289-290, 2017.


C. R. Young, J. G. Longhurst, M. B. Bowers, and C. M. Mazure, The expanding indications for clozapine, Experimental and Clinical Psychopharmacology, vol.5, issue.3, pp.216-234, 1997.

H. Yu, H. Yan, L. Wang, J. Li, L. Tan et al., Five novel loci associated with antipsychotic treatment response in patients with schizophrenia : A genome-wide association study, Antipsychotics Pharmacogenomics Consortium, vol.5, issue.4, pp.327-338, 2018.

S. Zhou, B. Wang, L. Yang, and J. Liu, Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2, Drug Metabolism Reviews, vol.42, issue.2, pp.268-354, 2010.

R. Zoccali, M. R. Muscatello, A. Bruno, R. Cambria, U. Micò et al., The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients : A double-blind, placebo-controlled study, Schizophrenia Research, vol.93, issue.1-3, pp.109-116, 2007.

S. H. Zorn, S. B. Jones, K. M. Ward, and D. R. Liston, Clozapine is a potent and selective muscarinic M4 receptor agonist, European Journal of Pharmacology, vol.269, issue.3, pp.1-2, 1994.

, , pp.90047-90054

R. La-clozapine, Un rapport CLZ/DMC élevé serait associé à une meilleure tolérance. Le polymorphisme génétique CYP1A2*1F (présent à 68% dans la population caucasienne) entraîne une augmentation de l'activité enzymatique. A l'état homozygote il serait associé à une moins bonne réponse à la clozapine, surtout chez les fumeurs. La fluvoxamine est un antidépresseur inhibiteur de la recapture de sérotonine ayant une action

. Le-génotypage-du-cyp1a2-n'a-pas-permis-d'associer-le-génotype-cyp1a2*1f/*1f-À-la-résistance-À-la-clozapine, Il a été constaté chez ces patients une corrélation entre la diminution du rapport CLZ/DMC et la consommation de tabac, de façon dose-dépendante. L'association à la fluvoxamine était corrélée à une augmentation dose-dépendante des rapports Concentration/Dose en clozapine et CLZ/DMC. Une évolution défavorable de la tolérance globale était corrélée à la clozapinémie

, La pharmacogénétique de la clozapine et son association à la fluvoxamine s'intègrent dans une approche de médecine personnalisée, afin d'individualiser le traitement des patients atteints de schizophrénie résistante, et ainsi de favoriser l'efficacité et de limiter les effets secondaires